KYMR – Kymera Therapeutics, Inc.

Float Short %

13.27

Margin Of Safety %

Put/Call OI Ratio

1.14

EPS Next Q Diff

-0.03

EPS Last/This Y

-0.49

EPS This/Next Y

-0.35

Price

85.68

Target Price

112.45

Analyst Recom

1.17

Performance Q

75.65

Relative Volume

1.15

Beta

2.19

Ticker: KYMR

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-17	KYMR	64.09	0.99	2.00	4461
2025-11-18	KYMR	64.32	0.99	0.17	4463
2025-11-19	KYMR	64.82	0.95	0.24	4566
2025-11-20	KYMR	64.62	0.94	0.45	4591
2025-11-21	KYMR	66	0.88	0.49	5112
2025-11-24	KYMR	65.58	0.80	0.38	6382
2025-11-25	KYMR	66.03	0.78	0.52	6745
2025-11-26	KYMR	67.9	0.75	0.69	7342
2025-12-01	KYMR	66.86	0.75	4.86	7412
2025-12-02	KYMR	64.33	0.91	13.09	8667
2025-12-03	KYMR	66.01	0.92	2.27	8430
2025-12-04	KYMR	66.23	0.98	3.70	8673
2025-12-05	KYMR	66.57	1.10	0.30	9164
2025-12-08	KYMR	94.23	1.07	2.22	9359
2025-12-09	KYMR	86.71	1.25	6.75	10662
2025-12-10	KYMR	89.86	1.17	0.84	10450
2025-12-11	KYMR	87.81	1.15	0.39	10627
2025-12-12	KYMR	89.16	1.14	0.67	10801
2025-12-15	KYMR	85.62	1.14	1.10	10910
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-17	KYMR	64.05	6.0	-16.8	-3.48
2025-11-18	KYMR	64.33	6.6	-22.5	-3.48
2025-11-19	KYMR	64.82	6.6	-24.4	-3.48
2025-11-20	KYMR	64.55	7.7	-19.7	-3.47
2025-11-21	KYMR	66.00	7.7	-29.7	-3.47
2025-11-24	KYMR	65.56	7.7	-18.2	-3.47
2025-11-25	KYMR	66.04	8.7	-24.1	-3.47
2025-11-26	KYMR	67.81	8.7	-31.0	-3.47
2025-12-01	KYMR	66.90	9.8	-16.6	-3.48
2025-12-02	KYMR	64.27	9.8	-8.2	-3.48
2025-12-03	KYMR	65.99	9.8	-31.0	-3.48
2025-12-04	KYMR	66.30	9.8	-23.3	-3.48
2025-12-05	KYMR	66.62	9.8	-23.7	-3.48
2025-12-08	KYMR	94.30	9.8	-	-3.48
2025-12-09	KYMR	86.88	9.8	4.9	-3.48
2025-12-10	KYMR	89.79	10.0	-33.0	-3.47
2025-12-11	KYMR	87.81	10.0	-13.8	-3.47
2025-12-12	KYMR	89.64	10.7	-28.7	-3.47
2025-12-15	KYMR	85.68	10.7	-6.7	-3.47
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-17	KYMR	6.00	6.28	13.52
2025-11-18	KYMR	6.00	6.28	13.52
2025-11-19	KYMR	6.00	6.28	13.52
2025-11-20	KYMR	6.00	6.28	13.52
2025-11-21	KYMR	6.00	6.28	13.52
2025-11-24	KYMR	6.02	3.40	13.51
2025-11-25	KYMR	6.07	3.40	13.51
2025-11-26	KYMR	6.07	3.40	14.41
2025-12-01	KYMR	6.07	3.34	14.41
2025-12-02	KYMR	6.07	3.34	14.41
2025-12-03	KYMR	6.07	3.34	14.41
2025-12-04	KYMR	6.55	3.34	14.41
2025-12-05	KYMR	6.55	3.34	14.41
2025-12-08	KYMR	6.55	3.37	14.41
2025-12-09	KYMR	5.16	3.37	14.41
2025-12-10	KYMR	5.16	3.37	14.58
2025-12-11	KYMR	26.76	3.37	14.58
2025-12-12	KYMR	26.82	3.37	14.58
2025-12-15	KYMR	21.26	3.03	13.27
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

[stock_market_widget type="chart" template="candlestick" assets="KYMR" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS

-0.94

Avg. EPS Est. Current Quarter

-0.79

Avg. EPS Est. Next Quarter

-0.97

Insider Transactions

21.26

Institutional Transactions

3.03

Beta

2.19

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

16.8

Max Drawdown 5-Year %

-87.5

Target Price

112.45

P/E

Forward P/E

PEG

P/S

154.68

P/B

6.5

P/Free Cash Flow

EPS

-3.6

Average EPS Est. Cur. Y

-3.47

EPS Next Y. (Est.)

-3.82

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-674.81

Relative Volume

1.15

Return on Equity vs Sector %

-58.2

Return on Equity vs Industry %

-43.1

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

-6.7

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”KYMR” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”KYMR” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”KYMR” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”KYMR” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”KYMR” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”KYMR” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”KYMR” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

Kymera Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 225

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

stock quote shares KYMR – Kymera Therapeutics, Inc. Stock Price stock today

news today KYMR – Kymera Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch KYMR – Kymera Therapeutics, Inc. yahoo finance google finance

stock history KYMR – Kymera Therapeutics, Inc. invest stock market

stock prices KYMR premarket after hours

ticker KYMR fair value insiders trading

KYMR – Kymera Therapeutics, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: KYMR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y